Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (February 2024)
8 slides from Pyc Therapeutics's investor presentation, Feb 2, 2024
Slide 1: Life-changing science: Investor Webinar Q1 2024
For personal use only Life-changing science Investor Webinar Q1 2024 February 2024
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the factors, many of which are outside PYC’s control. Important factors For personal use only business of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides that could cause actual results to differ materially from assumpti
Slide 3: PYC Therapeutics
PYC Therapeutics For personal use only • PYC is a precision medicine company progressing a pipeline of best-in-class drug candidates towards major unmet patient needs • Each drug candidate represents a significant commercial opportunity • In 2024, PYC will begin to generate the human safety and effi
Slide 4: PYC has multiple assets progressing towards major milestones
PYC has multiple assets progressing towards major unmet patient needs For personal use only Historical progress Progress expected within 12 months PROGRAM PRE-CLINICAL CLINICAL TRIALS MARKETED VP-001* Retinitis Pigmentosa Type 11 PYC-003 Polycystic Kidney Disease PYC-001 Autosomal Dominant Optic Atr
Slide 5: Strategy of developing best-in-class assets
PYC’s strategy sees it developing best-in-class assets 1 2 3 4 For personal use only Single gene Proven efficacy in For diseases caused Occurring inside Pillar disorders human 3D ‘mini- by insufficient gene cells organs’ expression >5x higher Leveraging PYC’s Clinical insights Where RNA drugs are Ra
Slide 6: Commercial opportunities are significant and the path to revenue generation is clear
PYC’s commercial opportunities are significant and the path to revenue generation is clear For personal use only Commercialisation² Indication Market size¹ 2028 2029 2030 Retinitis Pigmentosa 11 $1 billion p.a. Polycystic Kidney Disease $10 billion p.a. Optic Atrophy $2 billion p.a. 1. Market size i
Slide 7: Path to market sees human data read-outs within months
PYC’s path to market sees 5 human data read-outs within 36 months WITHIN 12 MONTHS WITHIN 24 MONTHS WITHIN 36 MONTHS For personal use only Formal safety read-out Safety + efficacy read-outs Registrational trial Retinitis Pigmentosa Type 11 (SAD) + efficacy insights (SAD+MAD) Safety read-out (SAD/MAD
Slide 8: Q&A
For personal use only Q&A PYC THERAPEUTICS 8
PYC Therapeutics — Investor Presentation (February 2024) on 6ix